NASDAQ:GERN

Geron Competitors

$1.44
+0.04 (+2.86 %)
(As of 04/21/2021 02:24 PM ET)
Add
Compare
Today's Range
$1.38
Now: $1.44
$1.44
50-Day Range
$1.40
MA: $1.65
$1.89
52-Week Range
$1.10
Now: $1.44
$2.40
Volume20,446 shs
Average Volume3.63 million shs
Market Capitalization$458.68 million
P/E RatioN/A
Dividend YieldN/A
Beta1.5

Competitors

Geron (NASDAQ:GERN) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying GERN stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Geron, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Geron (NASDAQ:GERN) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Risk and Volatility

Geron has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Geron and Amgen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Geron00503.00
Amgen091402.61

Geron currently has a consensus target price of $4.20, suggesting a potential upside of 196.82%. Amgen has a consensus target price of $261.1429, suggesting a potential upside of 1.07%. Given Geron's stronger consensus rating and higher probable upside, research analysts clearly believe Geron is more favorable than Amgen.

Institutional and Insider Ownership

55.5% of Geron shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 7.7% of Geron shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Geron and Amgen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Geron$460,000.00997.14$-68,550,000.00($0.36)-4.00
Amgen$23.36 billion6.38$7.84 billion$14.8217.46

Amgen has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Geron and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Geron-21,631.02%-43.76%-37.24%
Amgen29.42%95.55%15.52%

Summary

Amgen beats Geron on 9 of the 14 factors compared between the two stocks.

Geron (NASDAQ:GERN) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Geron and Gilead Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Geron00503.00
Gilead Sciences191302.52

Geron presently has a consensus price target of $4.20, indicating a potential upside of 196.82%. Gilead Sciences has a consensus price target of $97.68, indicating a potential upside of 46.27%. Given Geron's stronger consensus rating and higher probable upside, equities analysts clearly believe Geron is more favorable than Gilead Sciences.

Earnings & Valuation

This table compares Geron and Gilead Sciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Geron$460,000.00997.14$-68,550,000.00($0.36)-4.00
Gilead Sciences$22.45 billion3.75$5.39 billion$6.1410.88

Gilead Sciences has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

55.5% of Geron shares are held by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are held by institutional investors. 7.7% of Geron shares are held by company insiders. Comparatively, 0.1% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Geron and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Geron-21,631.02%-43.76%-37.24%
Gilead Sciences5.48%37.77%12.76%

Risk and Volatility

Geron has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Summary

Gilead Sciences beats Geron on 9 of the 14 factors compared between the two stocks.

Geron (NASDAQ:GERN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Geron and Vertex Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Geron00503.00
Vertex Pharmaceuticals042112.88

Geron presently has a consensus price target of $4.20, indicating a potential upside of 196.82%. Vertex Pharmaceuticals has a consensus price target of $293.2083, indicating a potential upside of 33.81%. Given Geron's stronger consensus rating and higher probable upside, equities research analysts plainly believe Geron is more favorable than Vertex Pharmaceuticals.

Valuation & Earnings

This table compares Geron and Vertex Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Geron$460,000.00997.14$-68,550,000.00($0.36)-4.00
Vertex Pharmaceuticals$4.16 billion13.67$1.18 billion$4.2951.24

Vertex Pharmaceuticals has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

55.5% of Geron shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 7.7% of Geron shares are held by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Geron and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Geron-21,631.02%-43.76%-37.24%
Vertex Pharmaceuticals38.51%28.55%20.68%

Volatility and Risk

Geron has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats Geron on 10 of the 15 factors compared between the two stocks.

Geron (NASDAQ:GERN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.

Risk & Volatility

Geron has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.

Valuation and Earnings

This table compares Geron and Regeneron Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Geron$460,000.00997.14$-68,550,000.00($0.36)-4.00
Regeneron Pharmaceuticals$7.86 billion6.88$2.12 billion$21.4723.52

Regeneron Pharmaceuticals has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

55.5% of Geron shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 7.7% of Geron shares are held by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Geron and Regeneron Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Geron00503.00
Regeneron Pharmaceuticals051412.80

Geron currently has a consensus price target of $4.20, indicating a potential upside of 196.82%. Regeneron Pharmaceuticals has a consensus price target of $644.1739, indicating a potential upside of 27.79%. Given Geron's stronger consensus rating and higher probable upside, analysts plainly believe Geron is more favorable than Regeneron Pharmaceuticals.

Profitability

This table compares Geron and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Geron-21,631.02%-43.76%-37.24%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Summary

Regeneron Pharmaceuticals beats Geron on 11 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Geron (NASDAQ:GERN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.

Risk and Volatility

Biogen has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Geron has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.

Institutional and Insider Ownership

83.5% of Biogen shares are owned by institutional investors. Comparatively, 55.5% of Geron shares are owned by institutional investors. 0.5% of Biogen shares are owned by company insiders. Comparatively, 7.7% of Geron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Biogen and Geron's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen35.63%51.00%23.54%
Geron-21,631.02%-43.76%-37.24%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Biogen and Geron, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen5141202.23
Geron00503.00

Biogen currently has a consensus target price of $303.3103, indicating a potential upside of 12.70%. Geron has a consensus target price of $4.20, indicating a potential upside of 196.82%. Given Geron's stronger consensus rating and higher possible upside, analysts clearly believe Geron is more favorable than Biogen.

Valuation & Earnings

This table compares Biogen and Geron's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion2.86$5.89 billion$33.578.03
Geron$460,000.00997.14$-68,550,000.00($0.36)-4.00

Biogen has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Summary

Biogen beats Geron on 9 of the 14 factors compared between the two stocks.

Geron (NASDAQ:GERN) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.

Risk & Volatility

Geron has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Institutional and Insider Ownership

55.5% of Geron shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 7.7% of Geron shares are owned by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Geron and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Geron-21,631.02%-43.76%-37.24%
Alexion Pharmaceuticals16.32%23.16%14.76%

Analyst Ratings

This is a summary of current ratings and recommmendations for Geron and Alexion Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Geron00503.00
Alexion Pharmaceuticals017412.27

Geron presently has a consensus price target of $4.20, indicating a potential upside of 196.82%. Alexion Pharmaceuticals has a consensus price target of $153.4286, indicating a potential downside of 8.82%. Given Geron's stronger consensus rating and higher possible upside, equities analysts plainly believe Geron is more favorable than Alexion Pharmaceuticals.

Earnings & Valuation

This table compares Geron and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Geron$460,000.00997.14$-68,550,000.00($0.36)-4.00
Alexion Pharmaceuticals$4.99 billion7.45$2.40 billion$9.7417.28

Alexion Pharmaceuticals has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Alexion Pharmaceuticals beats Geron on 9 of the 15 factors compared between the two stocks.


Geron Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$258.72+0.2%$149.21 billion$23.36 billion20.86Upcoming Earnings
Analyst Report
Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.8$66.78+0.6%$83.58 billion$22.45 billion68.85Analyst Report
Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$219.83+0.2%$56.98 billion$4.16 billion27.76Analyst Report
Analyst Revision
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$505.04+0.1%$54.04 billion$7.86 billion18.46Analyst Report
Biogen logo
BIIB
Biogen
1.9$269.52+1.4%$41.62 billion$14.38 billion8.92Upcoming Earnings
Analyst Report
Analyst Revision
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$168.34+1.1%$36.79 billion$4.99 billion39.33
Seagen logo
SGEN
Seagen
1.7$145.87+0.8%$26.25 billion$916.71 million57.43
Exact Sciences logo
EXAS
Exact Sciences
1.8$128.78+2.5%$21.24 billion$876.29 million-58.27Analyst Upgrade
Incyte logo
INCY
Incyte
1.6$84.33+0.3%$18.59 billion$2.16 billion-53.71
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$137.06+0.8%$15.96 billion$219.75 million-17.50Analyst Report
Novavax logo
NVAX
Novavax
1.2$211.71+1.7%$15.37 billion$18.66 million-40.56Insider Selling
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$79.18+0.3%$14.45 billion$1.70 billion18.12Analyst Report
Insider Selling
Repligen logo
RGEN
Repligen
1.5$216.76+2.2%$11.61 billion$270.24 million264.34Analyst Report
United Therapeutics logo
UTHR
United Therapeutics
1.5$210.89+1.6%$9.25 billion$1.45 billion19.95
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$97.41+1.3%$9.09 billion$788.10 million104.74Analyst Report
Analyst Revision
Exelixis logo
EXEL
Exelixis
1.9$24.85+1.4%$7.67 billion$967.78 million51.77Analyst Report
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$48.87+4.2%$6.71 billion$195.99 million305.44
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.56+1.0%$5.80 billion$1.12 billion86.58Analyst Report
Analyst Revision
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.83+1.6%$4.03 billion$806.43 million-9.61Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$66.00+0.6%$3.52 billion$1.11 billion21.22News Coverage
Gap Up
Alkermes logo
ALKS
Alkermes
1.2$20.53+1.8%$3.21 billion$1.17 billion-44.63Insider Selling
Analyst Revision
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.05+1.7%$3.16 billion$36.13 million-68.73
OPKO Health logo
OPK
OPKO Health
1.9$4.27+3.3%$2.77 billion$901.90 million-23.72
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.89+1.1%$2.59 billion$182.24 million-8.60Analyst Upgrade
Insider Selling
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.54+2.5%$2.44 billion$120.28 million-152.06Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$27.67+3.8%$2.05 billion$638.60 million-10.64Insider Selling
Gap Up
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$129.60+2.5%$2.02 billionN/A-11.71News Coverage
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$11.62+4.4%$1.97 billion$48.83 million-15.29
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.80+1.3%$1.72 billion$428.41 million15.65Analyst Upgrade
Unusual Options Activity
News Coverage
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.79+2.2%$1.66 billion$102.43 million-19.65
Codexis logo
CDXS
Codexis
1.3$23.79+3.8%$1.47 billion$68.46 million-67.97Analyst Report
Gap Up
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.49+2.3%$1.46 billion$82.27 million-18.27
Innoviva logo
INVA
Innoviva
1.4$12.11+1.1%$1.21 billion$261.02 million6.18News Coverage
MannKind logo
MNKD
MannKind
1.4$4.51+6.2%$1.05 billion$63.04 million-21.48Increase in Short Interest
News Coverage
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$9.17+2.5%$1.01 billion$35.22 million-6.69
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$25.34+6.6%$937.69 million$3.57 million-11.36
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.85+1.8%$908.31 million$227.19 million46.81Analyst Downgrade
News Coverage
Curis logo
CRIS
Curis
1.3$10.19+3.6%$898.72 million$10 million-12.43
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.77+2.4%$884.22 millionN/A0.00Gap Up
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.09+4.1%$704.45 million$322.07 million-4.85Upcoming Earnings
Decrease in Short Interest
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$21.07+1.3%$689.77 million$252 million-2.15
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.27+3.1%$682.20 million$150,000.00-4.67News Coverage
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.63+2.2%$603.93 million$59.29 million-24.20Increase in Short Interest
News Coverage
Clovis Oncology logo
CLVS
Clovis Oncology
1.2$5.94+4.5%$592.69 million$143.01 million-1.13
Agenus logo
AGEN
Agenus
1.6$2.83+5.7%$547.53 million$150.05 million-2.60
Verastem logo
VSTM
Verastem
1.1$2.82+3.9%$465.22 million$17.46 million-2.00
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$2.99+2.7%$447.35 million$109.33 million-2.20
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.57+7.1%$446.17 million$22.27 million-4.20Analyst Report
Insider Buying
Analyst Revision
News Coverage
Gap Down
XOMA logo
XOMA
XOMA
1.3$36.75+3.6%$398.98 million$18.37 million-33.11Increase in Short Interest
Gap Down
Fortress Biotech logo
FBIO
Fortress Biotech
1.6$4.22+5.0%$380.58 million$36.63 million-4.96Analyst Report
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.